Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.37
+0.7%		$16.93
$13.77
▼
$18.92
$6.21B0.56425,523 shs47,769 shs
PepGen, Inc. stock logo
PEPG
PepGen
$3.00
+0.5%		$2.59
$1.31
▼
$7.80
$207.43M1.971.05 million shs183,968 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%-4.28%+1.29%+15.10%+13.43%
PepGen, Inc. stock logo
PEPG
PepGen
0.00%-4.18%-0.33%+94.77%+101.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.37
+0.7%		$16.93
$13.77
▼
$18.92
$6.21B0.56425,523 shs47,769 shs
PepGen, Inc. stock logo
PEPG
PepGen
$3.00
+0.5%		$2.59
$1.31
▼
$7.80
$207.43M1.971.05 million shs183,968 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%-4.28%+1.29%+15.10%+13.43%
PepGen, Inc. stock logo
PEPG
PepGen
0.00%-4.18%-0.33%+94.77%+101.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.36
Hold$19.1510.26% Upside
PepGen, Inc. stock logo
PEPG
PepGen
2.71
Moderate Buy$11.50283.97% Upside

Current Analyst Ratings Breakdown

Latest BLCO and PEPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$24.00
9/9/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$24.00
9/9/2026
PepGen, Inc. stock logo
PEPG
PepGen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/28/2026
PepGen, Inc. stock logo
PEPG
PepGen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/28/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$21.00
8/21/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/7/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/3/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$20.00 ➝ $21.00
7/30/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$21.00
7/28/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$21.00
7/28/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$21.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.22$1.68 per share10.34$18.40 per share0.94
PepGen, Inc. stock logo
PEPG
PepGen
N/AN/AN/AN/A$2.14 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.48N/A16.540.54-3.21%4.14%1.93%11/4/2026 (Estimated)
PepGen, Inc. stock logo
PEPG
PepGen
-$89.65M-$1.31N/AN/AN/AN/A-51.01%-43.49%11/11/2026 (Estimated)

Latest BLCO and PEPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
PepGen, Inc. stock logo
PEPG
PepGen
-$0.2845-$0.26+$0.0245-$0.26N/AN/A
7/29/2026Q2 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.16$0.15-$0.01-$0.04$1.37 billion$1.39 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
PepGen, Inc. stock logo
PEPG
PepGen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.79
1.55
1.02
PepGen, Inc. stock logo
PEPG
PepGen
N/A
13.36
13.36

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
PepGen, Inc. stock logo
PEPG
PepGen
58.01%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
PepGen, Inc. stock logo
PEPG
PepGen
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000357.35 million352.17 millionOptionable
PepGen, Inc. stock logo
PEPG
PepGen
3069.26 million68.36 millionNot Optionable

Recent News About These Companies

PepGen (NASDAQ:PEPG) Earns Buy Rating from HC Wainwright
September 11 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31015830
PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-pepgen-inc-nasdaq-pepg-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-09-10/
HC Wainwright Reiterates Buy Rating for PepGen (NASDAQ:PEPG)
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-reiterates-buy-rating-for-pepgen-nasdaq-pepg-2026-09-09/
BlackRock Inc. Buys Shares of 1,304,262 PepGen, Inc. $PEPG
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-buys-shares-of-1304262-pepgen-inc-pepg-2026-09-06/
ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-acquires-new-shares-in-pepgen-inc-pepg-2026-08-26/
600,000 Shares in PepGen, Inc. $PEPG Purchased by AWM Investment Company Inc.
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-600000-shares-in-pepgen-inc-pepg-purchased-by-awm-investment-company-inc-2026-08-26/
GSA Capital Partners LLP Makes New Investment in PepGen, Inc. $PEPG
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-gsa-capital-partners-llp-makes-new-investment-in-pepgen-inc-pepg-2026-08-17/
PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Brokerages
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pepgen-inc-nasdaqpepg-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-08-16/
DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study
August 7, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/dsmb-approves-dose-escalation-in-pepgen-s-freedom2-dm1-study/ar-AA29C56B
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
August 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260806689062/en/PepGen-to-Advance-PGN-EDODM1-Into-Highest-Dose-Cohort-in-Phase-2-FREEDOM2-DM1-Study-Following-DSMB-Review/
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260806833210/en/pepgen-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights/
PepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo Finance
July 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PEPG/
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
July 8, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2023/10/12/pepgen-inc-announces-fda-has-lifted-the-clinical-hold-on-its-investigational-new
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2923962/pepgen-pepg-loses-14-3-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=cs-stocknewsapi-ft-tale_of_the_tape|rsi-2923962
10 Best NASDAQ Stocks Under $5 to Buy Right Now
May 18, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/10-best-nasdaq-stocks-under-5-to-buy-right-now-1763196/
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?
May 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/pepgen-pepg-one-best-nasdaq-044940753.html
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
May 13, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2920733/pepgen-pepg-upgraded-to-buy-here-s-what-you-should-know?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2920733
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512245445/en/pepgen-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
May 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pepgen-inc---pepg-302765207.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
April 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pepgen-inc---pepg-302759693.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3283277/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pepgen-inc-pepg.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$17.37 +0.12 (+0.70%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

PepGen stock logo

PepGen NASDAQ:PEPG

$3.00 +0.02 (+0.50%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas